The AlphaLISA™ immunoassay kit for human BTLA enables the quantitative determination of human B- and T-lymphocyte attenuator (BTLA, CD272) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein Quantification |
Dynamic Range | 11 - 300,000 pg/mL |
Limit of Detection | 11 pg/mL |
Limit of Quantification | 38 pg/mL |
Sample Volume | 5 µL |
The AlphaLISA™ immunoassay kit for human BTLA enables the quantitative determination of human B- and T-lymphocyte attenuator (BTLA, CD272) in serum, buffered solution, and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Formats:
Features:
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
B- and T-lymphocyte attenuator (BTLA), also known as CD272, is a 35 kDa transmembrane protein that is expressed on Th1 cells, B cells and NK cells. BTLA's main function is to regulate T cell activation by acting as an inhibitor when interacting with HVEM, B7-H4 and TNF receptors. Deletion of BTLA results in the overproduction of T cells, especially CD8+ cancer specific memory T cells. Higher expression of BTLA is correlated to patients with lung cancer and sepsis. This kit is designed to detect and quantify the levels of BTLA in cell culture supernatant and serum.
Application |
Protein Quantification
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA
|
Detection Modality |
Alpha
|
Dynamic Range |
11 - 300,000 pg/mL
|
Limit of Detection |
11 pg/mL
|
Limit of Quantification |
38 pg/mL
|
Product Group |
Kit
|
Sample Volume |
5 µL
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
BTLA
|
Target Class |
Biomarkers
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Oncology
|
Unit Size |
500 Assay Points
|
Are you looking for resources, click on the resource type to explore further.
Advance your autoimmune disease research and benefit from Revvity broad offering of reagent technologies
Chimeric antigen receptor (CAR) T-cell therapy has transformed the field of immuno-oncology providing a novel approach to treating...
We are here to answer your questions.